CytaCoat coating inactivates SARS-CoV-2 (COVID-19)

CytaCoat coating inactivates SARS-CoV-2 (COVID-19)

CytaCoat coating inactivates SARS-CoV-2 (COVID-19) Press release Stockholm, July 9, 2020   The study was performed by the University of Tennessee Health Science Center (UTHSC) Regional Bioconception Laboratory, in May 2020. Silicone with and without CytaCoat...
New Issue in October 2019

New Issue in October 2019

In October 2019 CytaCoat raised €460 k (SEK 5 million) in an oversubscribed New Issue. The funds will be used to continue the prototype development of coated medical devices and commercialization of the CytaCoat technology. It will also allow CytaCoat to make key...
CytaCoat is moving to a new laboratory!

CytaCoat is moving to a new laboratory!

CytaCoat is moving to a new laboratory!  As the next step of it’s development, CytaCoat is moving to a new loboratory where both pilot plant production and testing of our unique antimicrobial coating can be performed. This enables CytaCoat to respond to an increasing...
CytaCoat awarded a Seal of Excellence in EIC Accelerator

CytaCoat awarded a Seal of Excellence in EIC Accelerator

Project name: CYTAMED   “The project “A universal life-saving protection for medical devices – a new tool for reduction of hospital infections in the global battle against antibiotic resistance”, proposal 946737, was awarded a “Seal of Excellence” in November...